Advertisement
BIIB vs BMY
Which Stock Would AI Choose? Biogen Inc. (BIIB) vs. Bristol-Myers Squibb Company (BMY) Stock Comparison
Key Takeaways
- BIIB has delivered strong one-year returns of over 50%, outperforming broader markets despite recent monthly pullbacks.
- BMY shows year-to-date gains around 12%, supported by growth in its oncology portfolio amid stable pharmaceutical demand.
- Both stocks face upcoming Q1 2026 earnings with expected revenue pressures, but BIIB benefits from recent analyst upgrades and momentum in neurology treatments.
- BMY offers a larger market cap and diversified revenue, providing relative stability compared to BIIB's higher volatility.
- AI tools highlight BIIB's trend consistency in recent market activity, edging out BMY on relative performance metrics.
Introduction
Biogen Inc. (BIIB) and Bristol-Myers Squibb Company (BMY) represent key players in the biotechnology and pharmaceutical sectors, focusing on neurology and oncology treatments, respectively. This stock comparison evaluates their recent market performance, business drivers, and positioning amid evolving healthcare demands. Traders seeking momentum plays may eye BIIB's upside potential, while long-term investors might prefer BMY's scale and pipeline diversity. With both facing earnings scrutiny, understanding relative strengths in price behavior, sentiment, and catalysts aids informed decision-making in the current environment.
BIIB Overview and Recent Performance
Biogen Inc. (BIIB) specializes in neurology therapeutics, including multiple sclerosis (MS) drugs and Alzheimer's treatments like LEQEMBI. In recent market activity, BIIB shares have shown resilience, posting over 50% gains over the past year despite a modest year-to-date advance of around 4-5%. Q4 2025 earnings beat expectations with adjusted EPS (earnings per share) of $1.99 and revenue of $2.28 billion, bolstered by growth products up 6%. However, MS portfolio declines and an anticipated 7% revenue dip in upcoming Q1 results have tempered enthusiasm, leading to weekly and monthly dips of 1-4%. Analyst upgrades reflect optimism around pipeline catalysts, influencing positive sentiment shifts.
BMY Overview and Recent Performance
Bristol-Myers Squibb Company (BMY) is a global biopharma leader with a focus on oncology, immunology, and cardiovascular therapies, highlighted by Opdivo. Recent weeks have seen BMY deliver year-to-date returns near 12%, outpacing BIIB, though shares hover around $59-60 amid sector volatility. Q4 2025 results showed revenues up 1% to $12.5 billion, driven by 16% growth in its portfolio, yet forecasts signal a 20% EPS decline and 2.5% revenue drop for Q1 2026. Daily gains in recent sessions underscore steady demand, but broader pressures on legacy products have contributed to mixed momentum and cautious trader sentiment.
Trending AI Robots
Tickeron's Trending AI Robots page curates the top 25 AI trading bots from a platform hosting 351 total bots that analyze thousands of tickers across diverse strategies. These bots employ varied approaches, including signal generation, virtual portfolio management, and brokerage execution, with timeframes from intraday to long-term swings. Selected for superior adaptation to current market conditions, they showcase strong historical performances tailored to volatility in sectors like biotech. Traders can explore bots optimized for stocks like BIIB and BMY, leveraging data-driven signals for relative performance edges. Visit Trending AI Robots to discover bots matching your trading style.
Head-to-Head Comparison
BIIB and BMY both operate in biotech but diverge in focus: BIIB's neurology emphasis offers higher growth potential via Alzheimer's innovations, contrasting BMY's diversified oncology and cardio exposure for steadier cash flows. Recent momentum favors BIIB with 50%+ annual returns versus BMY's more modest gains, though BMY's $118 billion market cap dwarfs BIIB's $26 billion, implying lower beta risk. Sentiment tilts toward BIIB on upgrades, while BMY contends with patent cliffs; trade-offs center on volatility versus stability in sector headwinds.
Tickeron AI Verdict
Tickeron's AI currently leans toward BIIB due to superior trend consistency over the past year, bolstered by earnings beats and neurology catalysts positioning it for potential outperformance. While BMY provides defensive scale, BIIB's relative momentum and analyst support suggest higher probabilistic upside in the near term, contingent on earnings execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BIIB is a Hold and BMY is a StrongBuy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BIIB’s FA Score shows that 1 FA rating(s) are green whileBMY’s FA Score has 1 green FA rating(s).
- BIIB’s FA Score: 1 green, 4 red.
- BMY’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BIIB’s TA Score shows that 6 TA indicator(s) are bullish while BMY’s TA Score has 2 bullish TA indicator(s).
- BIIB’s TA Score: 6 bullish, 3 bearish.
- BMY’s TA Score: 2 bullish, 7 bearish.
Price Growth
BIIB (@Pharmaceuticals: Major) experienced а +5.74% price change this week, while BMY (@Pharmaceuticals: Major) price change was -3.54% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was -0.35%. For the same industry, the average monthly price growth was -1.12%, and the average quarterly price growth was +2.63%.
Reported Earning Dates
BIIB is expected to report earnings on Jul 16, 2026.
BMY is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Pharmaceuticals: Major (-0.35% weekly)The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.
| BIIB | BMY | BIIB / BMY | |
| Capitalization | 28.6B | 115B | 25% |
| EBITDA | 2.7B | 15B | 18% |
| Gain YTD | 12.478 | 6.432 | 194% |
| P/E Ratio | 21.28 | 15.73 | 135% |
| Revenue | 9.94B | 48.5B | 20% |
| Total Cash | 4.28B | 10.5B | 41% |
| Total Debt | 6.56B | 46.4B | 14% |
BIIB | BMY | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 50 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 89 Overvalued | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 89 | |
SMR RATING 1..100 | 77 | 24 | |
PRICE GROWTH RATING 1..100 | 44 | 53 | |
P/E GROWTH RATING 1..100 | 13 | 63 | |
SEASONALITY SCORE 1..100 | 85 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
BMY's Valuation (38) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (89) in the Biotechnology industry. This means that BMY’s stock grew somewhat faster than BIIB’s over the last 12 months.
BMY's Profit vs Risk Rating (89) in the Pharmaceuticals Major industry is in the same range as BIIB (100) in the Biotechnology industry. This means that BMY’s stock grew similarly to BIIB’s over the last 12 months.
BMY's SMR Rating (24) in the Pharmaceuticals Major industry is somewhat better than the same rating for BIIB (77) in the Biotechnology industry. This means that BMY’s stock grew somewhat faster than BIIB’s over the last 12 months.
BIIB's Price Growth Rating (44) in the Biotechnology industry is in the same range as BMY (53) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew similarly to BMY’s over the last 12 months.
BIIB's P/E Growth Rating (13) in the Biotechnology industry is somewhat better than the same rating for BMY (63) in the Pharmaceuticals Major industry. This means that BIIB’s stock grew somewhat faster than BMY’s over the last 12 months.
| BIIB | BMY | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 4 days ago 65% | 4 days ago 60% |
| Momentum ODDS (%) | 4 days ago 56% | 4 days ago 59% |
| MACD ODDS (%) | 4 days ago 61% | 4 days ago 46% |
| TrendWeek ODDS (%) | 4 days ago 57% | 4 days ago 55% |
| TrendMonth ODDS (%) | 4 days ago 57% | 4 days ago 56% |
| Advances ODDS (%) | 4 days ago 56% | 25 days ago 54% |
| Declines ODDS (%) | 11 days ago 72% | 4 days ago 53% |
| BollingerBands ODDS (%) | 4 days ago 68% | 4 days ago 59% |
| Aroon ODDS (%) | 4 days ago 55% | 4 days ago 55% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SCHA | 33.46 | 0.43 | +1.30% |
| Schwab US Small-Cap ETF™ | |||
| BOE | 11.90 | 0.02 | +0.17% |
| BlackRock Enhanced Global Dividend Trust | |||
| GUMI | 50.31 | 0.03 | +0.06% |
| Goldman Sachs Ultra Shrt Muncpl Inc ETF | |||
| NDVG | 33.68 | N/A | N/A |
| Nuveen Dividend Growth ETF | |||
| SIHY | 45.23 | -0.05 | -0.11% |
| Harbor Ares Systematic High-Yield ETF | |||
BMY and
Correlation & Price change
A.I.dvisor indicates that over the last year, BMY has been loosely correlated with PFE. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if BMY jumps, then PFE could also see price increases.
| Ticker / NAME | Correlation To BMY | 1D Price Change % | ||
|---|---|---|---|---|
| BMY | 100% | -0.16% | ||
| PFE - BMY | 63% Loosely correlated | -1.42% | ||
| AMGN - BMY | 58% Loosely correlated | +0.79% | ||
| ABBV - BMY | 57% Loosely correlated | -0.57% | ||
| MRK - BMY | 56% Loosely correlated | -0.82% | ||
| BIIB - BMY | 54% Loosely correlated | +1.08% | ||
More | ||||